Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 11,850.00
Ask: 12,300.00
Change: 0.00 (0.00%)
Spread: 450.00 (3.797%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,190.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Von der Leyen faces scrutiny over shaky EU vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Faces grilling at four EU lawmaker group meetings

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Adds EU lawmaker meetings, and comments by MEP, senior
diplomat)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU chief executive Ursula von
der Leyen on Tuesday faced hours of questioning by lawmakers
over the European Commission's vaccine strategy, focusing on a
slow roll-out and an export control plan that dismayed Britain
and Ireland.

Questions still surround the Commission's decision - swiftly
reversed - to invoke Article 16 of the Brexit agreement's
Northern Ireland protocol, a move that would have set up border
checks on the island of Ireland.

Von der Leyen, who has tweeted and appeared only on German
television since the bloc mandated authorisation for vaccine
exports, will be quizzed in meetings of three European
Parliament groupings on Tuesday evening and another on Wednesday
morning.

Sophie in 't Veld, a Dutch liberal lawmaker, said before her
group met that von der Leyen was relying on too narrow a circle
of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

A senior EU diplomat said von der Leyen's position was
probably safe with a closing of ranks around the Commission, but
there would be "some unpleasantness in coming days".

Senior British minister Michael Gove, who is to meet his
Commission counterpart on Wednesday, said London's trust in
Brussels had been eroded and that the two must resolve serious
problems over post-Brexit trade arrangements for Northern
Ireland.

REGRET OVER 'PROVISIONAL' DECISION

In interviews with newspapers outside Germany, the European
Commission president sought to defuse criticism over the EU's
slow start to COVID-19 vaccinations and outrage over the border
checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

In similar comments to France's Le Monde she said: "When you
take urgent decisions - in this year of crisis, the Commission
has taken almost 900 - there is always a risk of missing
something."

The vaccine crisis, which came to a head with EU export
controls announced on Friday, followed news that AstraZeneca
would cut its supply of vaccines to the bloc until March
by 60% due to production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the supply problems should ease in the
second quarter of 2021, with more production capacity for
BioNTech/Pfizer and other potential approvals
of vaccines, including from Johnson & Johnson.

The Commission has ordered 2.3 billion doses from six
producers, far more than the bloc requires. Production, though,
was an enormous challenge, with clear teething problems.

"I see it as a marathon in which we have only covered the
first kilometres," she told Dutch newspaper De Volkskrant.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones and Angus MacSwan)

More News
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.